A Health Care Portolio for the Ages: Checkup Motley Fool After a predefined interim analysis, idelalisib showed a large and statistically significant improvement to progression-free survival when added to rituximab as a second-line treatment. Those results have earned idelalisib breakthrough designation, as ... |
